Table 2.
Classification of current MET target therapies, and clinical trial results, approved by FDA.
| Drug’s Type | Drug Name | Clinical Trial | Alterations | ORR | DOR | PFS | Disease Control Rate |
|---|---|---|---|---|---|---|---|
| (Months) | (Months) | ||||||
| Selective type Ia | Crizotinib | PROFILE-1001 | METex14 | 32% | 9.1 | 7.3 | |
| Multitarget TKIs | (NCT00585195) | GCN ≥1.8–≤ 2.2 |
33% | 12.1 | 1.8 | ||
| GCN ≥2.2–≤ 4 |
14.3% | 3.7 | 1.9 | ||||
| GCN > 4 | 40% | 5.5 | 6.7 | ||||
| Selective type Ib monotarget MET TKIs | Capmatinib | GEOMETRY mono-1 trial (NCT02414139) | METex14 | 40.6% previously treated | 9.7 | 5.4 | 78% |
| 67.9% treatment-naive | 12.6 | 12.4 | 96% | ||||
| NCT01324479 | MET GCN > 6 | 47% | N.S | 9.3 | 80% | ||
| Tepotinib | VISION trial (NCT02864992) | METex14 | 46% | 11.1 | 8.5 | 65.70% | |
| Savolitinib | (NCT02897479) | METex14 | 49.2% | - | 6.9 months | 93.40% |